Sugi Predict

Sugi Predict / Compounds / SCHEMBL400070

SCHEMBL400070

SCHEMBL400070

O=c1[nH]c(-c2ccccc2)nc2cc(Cl)ccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 8/20 0.73
▸ TNKS2 Q9H2K2 8/20 0.73
▸ GUSB P08236 5/20 0.73
▸ PARP2 Q9UGN5 2/20 0.73
▸ PARP1 P09874 5/20 0.69
▸ CYP1A1 P04798 2/20 0.60
▸ CYP1B1 Q16678 2/20 0.60
▸ CYP1A2 P05177 1/20 0.60
▸ TUBB4A P04350 1/20 0.59
▸ TUBB P07437 1/20 0.59
▸ TUBA3C P0DPH7 1/20 0.59
▸ TUBA1B P68363 1/20 0.59
▸ TUBA4A P68366 1/20 0.59
▸ TUBB4B P68371 1/20 0.59
▸ TUBB3 Q13509 1/20 0.59
▸ TUBB2A Q13885 1/20 0.59
▸ TUBB8 Q3ZCM7 1/20 0.59
▸ TUBA3E Q6PEY2 1/20 0.59
▸ TUBA1A Q71U36 1/20 0.59
▸ TUBA1C Q9BQE3 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29764046 1.00 TNKS (0.73) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL27740408 0.89 TNKS (0.70) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL30112572 0.89 TNKS (0.70) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL3980635 0.85 TNKS (0.65) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL11078935 0.85 NPC1 (0.71) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL8618931 0.84 TNKS (1.00) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL2617083 0.84 TNKS (0.77) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL11821683 0.84 TNKS (0.71) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL29592833 0.82 TNKS (1.00) TNKSTNKS2GUSBPARP2PARP1
SCHEMBL258433 0.82 TNKS (1.00) TNKSTNKS2GUSBPARP2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115650924-B Green synthesis method of quinazolinone 山东华泰新材料技术研发有限公司 2024-08-20 — — CN disclosed
CN-115650924-A Green synthesis method of quinazolinone 上海橡实化学有限公司 2023-01-31 — — CN disclosed
CN-113185468-B Method for synthesizing quinazolinone through photocatalysis 上海橡实化学有限公司 2022-08-26 — — CN disclosed
CN-113461617-A Method for preparing N-heterocycle through visible light mediated dehydrogenation 石河子大学 2021-10-01 — — CN disclosed
CN-113185468-A Method for synthesizing quinazolinone through photocatalysis 上海橡实化学有限公司 2021-07-30 — — CN disclosed
CN-106518789-B A method of synthesis Quinazol derivative 南京理工大学 2019-04-16 — — CN disclosed
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
CN-106518789-A Method for synthesis of quinazolinone derivative 南京理工大学 2017-03-22 — — CN disclosed
CN-106478525-A A kind of method of synthesis quinazolone 南京理工大学 2017-03-08 — — CN disclosed
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
EP-1740591-B1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2009-06-17 — — EP disclosed
EP-1740591-B1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2009-06-17 — — EP disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
EP-1740591-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2007-01-10 — — EP disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed
WO-2005097800-A1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNKS 2070/4885TNKS2 1972/4885GUSB 3740/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNKS 2070/4885TNKS2 1972/4885GUSB 3740/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 TNKS 2070/4885TNKS2 1972/4885GUSB 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.